Consumer products giant Clorox (NYSE:CLX) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 8% year on year to $1.67 billion. Its non-GAAP profit of $1.45 per share was 6.9% below analysts’ consensus estimates.
Is now the time to buy Clorox? Find out in our full research report.
-
Revenue: $1.67 billion vs analyst estimates of $1.72 billion (8% year-on-year decline, 3.3% miss)
-
Adjusted EPS: $1.45 vs analyst expectations of $1.56 (6.9% miss)
-
Management reiterated its full-year Adjusted EPS guidance of $7.15 at the midpoint
-
Operating Margin: 15.2%, up from 12.9% in the same quarter last year
-
Organic Revenue fell 2% year on year (2% in the same quarter last year)
-
Market Capitalization: $17.13 billion
“In the third quarter, heightened macroeconomic uncertainties drove changes in shopping behaviors, resulting in temporary category slowdowns and lower sales. We expect these slowdowns to persist in the fourth quarter, as reflected in our updated outlook,” said Chair and CEO Linda Rendle.
Founded in 1913 with bleach as the sole product offering, Clorox (NYSE:CLX) today is a consumer products giant whose product portfolio spans everything from bleach to skincare to salad dressing to kitty litter.
Examining a company’s long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul.
With $7.02 billion in revenue over the past 12 months, Clorox is one of the larger consumer staples companies and benefits from a well-known brand that influences purchasing decisions. However, its scale is a double-edged sword because there are only a finite number of major retail partners, placing a ceiling on its growth. To expand meaningfully, Clorox likely needs to tweak its prices, innovate with new products, or enter new markets.
As you can see below, Clorox struggled to increase demand as its $7.02 billion of sales for the trailing 12 months was close to its revenue three years ago. This shows demand was soft, a tough starting point for our analysis.
This quarter, Clorox missed Wall Street’s estimates and reported a rather uninspiring 8% year-on-year revenue decline, generating $1.67 billion of revenue.
Looking ahead, sell-side analysts expect revenue to grow 1.9% over the next 12 months. Although this projection indicates its newer products will catalyze better top-line performance, it is still below average for the sector.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
